• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Consumer Cyclical·7413.T
Share

Sokensha Co.,Ltd. Stocks

¥ 2951Last Updated 20.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

¥ 13.19M

¥ 2951
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sokensha Co.,Ltd. serves as a wholesale distributor for a diverse range of natural, health-conscious, and related merchandise across Japan. Their extensive product portfolio features items such as culinary oils, margarine, various seasonings, prepared foods, pasta, grains, dried provisions including seaweed, an assortment of drinks and wines, teas, confectionery, dietary supplements, gift selections, beauty products, and personal hygiene essentials, alongside special seasonal offerings for holidays. This company was founded in 1950 and maintains its headquarters in Yokohama, Japan.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.10.2026 21:47

"A Roller-Coaster Ride for Stocks": What Wall Street Is Saying Ahead of SpaceX's Earnings Report

20.10.2026 20:36

Why Cathie Wood's team expects Tesla's stock to rise by more than 1,000%

20.10.2026 20:11

"A Vicious Cycle": What Risks Does Rising Bond Yields Pose to the Stock Market?

20.10.2026 19:39

"The Weak Link": The risk premium on French government bonds has approached a 15-year high

20.10.2026 19:05

Veradermics jumps on successful hair-loss pill trial. Is the stock a buy?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026